RxDoctor Payments Data

Katherine Mortati, MD

Neurology · Ny, NYNPI 1740257393

Payments from drug & device makers

$2,746in general payments, 2019–2025

Across 55 payments — averaging $49.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuropace, Inc.$2K
  • SK Life Science, Inc.$576
  • Neurelis, Inc.$124
  • Jazz Pharmaceuticals Inc.$95
  • UCB, Inc.$69
  • Ceribell, Inc.$61
  • plus $159 from 5 others

What the payments were for

  • Travel & lodging$1,48754%
  • Food & beverage$1,25946%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,746 in reported general payments places this provider in the 55th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$30,338
Medicare patients
94
Services billed
224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate23$34,096
Oxtellar XrOxcarbazepine24$30,124
BriviactBrivaracetam20$23,481
Lamotrigine ErLamotrigine34$17,433
Lacosamide94$9,914
Levetiracetam134$5,330
Levetiracetam ErLevetiracetam34$3,456
Carbamazepine ErCarbamazepine26$3,143
Oxcarbazepine58$2,852
Divalproex Sodium26$2,267
Clobazam24$2,010
Divalproex Sodium ErDivalproex Sodium67$1,890
DilantinPhenytoin Sodium Extended18$1,436
Zonisamide48$1,404
Phenobarbital33$1,297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$576$34,09623 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$14$30,12424 claims
UCB, Inc.Briviact$69$23,48120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,623 neurology providers in New York.

Other neurology in Ny

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →